NL-OMON34077招募中3 期
Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab - Prospective intervention of candesartan
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 160 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •cytologically or histologically confirmed primary breast cancer
排除标准
- •history of hypersensitivity for the study medication
研究者
相似试验
进行中（未招募）
不适用
Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab - M06HERWHO: 0-2 Serum creatinine <140 umol/l Thyroid stimulating hormone between 0.5-3.9 MU/l. Blood pressure systolic = 140 mmHg diastolic = 90 mmHg is acceptable at randomization. LVEF ? 50% assessed by multigated angiography (MUGA) or cardiac ultrasoundEUCTR2006-001707-11-NLKI-Av
已完成
不适用
Study to compare the effect of Trehalose over sodium hyaluronate in patients of dry eye diseaseCTRI/2020/04/024605Dr Arvind Kumar Morya384
尚未招募
4 期
Drug trial between Dapagliflozin with existing drug Saroglitazar in patients with Non alcoholic fatty liver disease and diabetesCTRI/2023/12/060736Deepthi v
进行中（未招募）
1 期
Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information - Safety of Gadovist® in Renally Impaired Patients (the GRIP study)Patients with moderate to severe renal impairment.MedDRA version: 9.1Level: LLTClassification code 10038474Term: Renal insufficiencyEUCTR2008-004496-22-FRBayer Health Care AG (study performed by Bayer Schering Pharma AG)926
进行中（未招募）
不适用
Saftey of Primovist/Eovist in Renally Impaired patientsPatients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist.MedDRA version: 15.1Level: LLTClassification code 10038469Term: Renal impairment NOSSystem Organ Class: 100000004857EUCTR2008-005867-33-DEBayer HealthCare AG1,000